-
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
Custom ELISA Kits(Page)Custom ELISA Kit Development Service | Assay Genie
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Cell Synchronisation Methods(Post)Cell Culture · ProtocolsCell Synchronisation Methods: Protocols for G1, S, G2 and M Phase ArrestAn asynchronous culture contains cells at every stage of the cycle at once, so any measurement is an ave
Adipokines and Insulin Signaling Pathways: An In-Depth Exploration(Post)The prevalence of obesity and its associated metabolic disorders has risen dramatically in recent decades, presenting a significant global health challenge. Adipose tissue, once considered mere
PI3K / AKT / mTOR Signalling in T Cells(Page) Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Adenosine Axis — CD39, CD73 and A2A Receptors(Page) Platinum based cancer drugs and next generation therapeutics(Post)Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics
Comprehensive Analysis of Antibody Structure and Function(Post)Antibodies, or immunoglobulins, stand as critical components of the immune system, orchestrating the identification and neutralization of pathogens like viruses and bacteria. This extensive artic
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
p38 MAPK Signaling Review(Post)The p38 MAPK signaling pathway is an intracellular signaling pathway that plays a crucial role in cellular responses to various stressors and inflammatory stimuli. It is a part of the larger MAPK
TLR Innate Sensing Pathway: Receptors, MyD88/TRIF and Assays(Post)Toll-like receptors are the reason a milligram of endotoxin can kill a mouse. They are the fastest, least discriminating layer of immunity: germline-encoded sensors that read conserved microbial chem
No Ligand, No Kinase, No Problem(Post)HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
EGFR Pathway and YAP in Non-Small Cell Lung Cancer(Post)Understanding the EGFR Pathway and YAP in Non-Small Cell Lung CancerThe epidermal growth factor receptor (EGFR) pathway plays a pivotal role in the development and progression of non-small cell lung c
Citrullination, NETs and Rheumatoid Arthritis(Page) Dual PD-1/PD-L2 Blockade: Expanding the Horizons of Cancer Immunotherapy(Post)Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi
How do antibodies work?(Post)Antibodies are a special class of Y shaped proteins that help guard your body from invading viruses and bacteria. They do this by either neutralizing the dangerous substance
Mesenchymal Stem Cell Differentiation Pathways: Unraveling Lineage-Specific Markers(Post)The intricate process of mesenchymal stem cell (MSC) differentiation is a cornerstone of developmental biology and regenerative medicine. Mesenchymal stem cells, renowned for their self-renewal ca
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C